September 2021: Research Update

A highlight of all our trial and research achievements this past month:

MONARCC protocol published

Congratulations to the MONARCC colorectal cancer trial team who have had their trial protocol published in BMC Cancer.

Led by Dr Matthew Burge, the trial is studying the potential of using a ‘lighter’ chemotherapy regimen, 5 flurouracil, together with the antibody treatment panitumumab. It is also testing the effectiveness of using panitumumab by itself. These options could provide effective cancer control while minimising side effects. This Innovation Grant awarded trial closed to patient enrolment last month. 


RoLaCaRT-1 enrols first patient

The first patient has been randomised to the RoLaCaRT-1 colon cancer trial at the Peter MacCallum Cancer Centre. RoLaCaRT-1 is a new surgical clinical trial comparing robotic surgery to keyhole surgery for people with colon cancer. Led by Professor Andrew Stevenson, the RoLaCaRT-1 trial is the first of its kind in the world to determine the benefits of robotic surgery to laparoscopy.

The trial is also set to enrol patients at Cabrini Hospital in Victoria, Sydney Adventist Hospital and Prince of Wales Hospital in New South Wales, and The Queen Elizabeth Hospital in South Australia. It is opening soon at another five hospitals in Australia, two UK hospitals and at two Mayo clinics in the US. Congratulations to the trial team!


INTEGRATE IIb now recruiting in Japan

The INTEGRATE IIb stomach cancer trial’s first international patient has been enrolled in Japan. This trial is assessing a combination of drugs (regorafenib and nivolumab) to improve the overall survival rate for Advanced Gastro-oesophageal Carcinoma (AGOC) patients. This will be compared with the current standard chemotherapy treatment. Congratulations to the INTEGRATE IIb team and thank you to the patients involved. Learn more about this trial and previous INTEGRATE trials.   


MODULATE and INTEGRATE II to be presented at ESMO

Congratulations to the MODULATE colorectal cancer trial team and the INTEGRATE II gastro-oesophageal cancer trial team, for being accepted for virtual presentation at the upcoming ESMO conference. MODULATE completed patient recruitment in 2020, and will present a ‘results submitted’ poster, and INTEGRATE II will present a ‘trials in progress’ poster.

MODULATE, led by Professor Niall Tebbutt tested the efficacy, safety, and tolerability of an experimental drug combination in patients with metastatic colorectal cancer who have previously failed standard of care treatment. INTEGRATE II, led by Professor Nick Pavlakis is seeking to determine whether Regorafenib improves overall survival as a third line therapy in refractory AGOC.


Trials closing to patient enrolment soon

DYNAMIC-Rectal: Aiming to show that a ctDNA-based approach to adjuvant therapy will lead to substantially less patients receiving adjuvant therapy. Patient enrolment closing 31 September 2021. 

NABNEC, a randomised phase II trial of patients with grade 3 neuroendocrine carcinomas (NECs) aiming to determine the safety and efficacy of carboplatin plus nab-paclitaxel in comparison with carboplatin plus etoposide. Patient enrolment closing 31 December 2021. 


Spotlight on Oesophageal and Gastro-Oesophageal cancer trials

This month, we’re spotlighting our open oesphageal and gastro-oesophageal cancer trials looking to boost patient enrolment.

  • INTEGRATE IIb: Aiming to determine if the regorafenib and nivolumab combination improves overall survival compared with current standard chemotherapy options in refractory AGOC.
  • NEO-CREATE: Assessing the safety of adding the drug avelumab to chemo-radiation using two standard chemotherapy drugs before surgery. 
  • PALEO: Investigating the effects of the adding SBRT to treatment with nivolumab.  

View all AGITG open trials.